Lead Sponsor

Millennium Pharmaceuticals, Inc.

Collaborators

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Male or female subjects 18 years or older
•Histologically proven diagnosis of follicular non-Hodgkin's lymphoma grades 1or 2 according to the World Health Organization classification
•Subjects must have received at least 12 doses (375mg/m2 or appropriately adjusted dose) of rituximab for the treatment of this lymphoma as single agent rituximab or in rituximab-containing regimens as documented in the subject's medical record
•Documented relapse or progression following last antineoplastic treatment
•At least 1 measurable tumor mass (≥1.5 cm x ≥1.0 cm)

•Subjects with histological or clinical transformation to an aggressive lymphoma
•* prior treatment with VELCADE or fludarabine.
•* antineoplastic (including unconjugated therapeutic antibodies), experimental, or radiation therapy within 3 weeks before randomization
•* nitrosoureas within 6 weeks before randomization
•* radioimmunoconjugates or toxin immunoconjugates within 10 weeks before randomization
•* major surgery within 3 weeks before randomization
•* chronic use of corticosteroids, such as dexamethasone